ライフサイエンスコーパス: pharmacokinetic parameter

1 pockets so as to improve affinity and adjust pharmacokinetic parameters.

2 in, with negligible interdose variability in pharmacokinetic parameters.

3 for chronic HBV disease using HBIg dosed by pharmacokinetic parameters.

4 lar potency, drug target residence time, and pharmacokinetic parameters.

5 le-cell antitubercular activity, and in vivo pharmacokinetic parameters.

6 on interaction with human GlgB and in silico pharmacokinetic parameters.

7 ts by two SP (deviations < 15%), and correct pharmacokinetic parameters.

8 n administration did not influence melphalan pharmacokinetic parameters.

9 yl-JNJ-31020028 is sufficient for estimating pharmacokinetic parameters.

10 ex and subsequently estimate tissue-specific pharmacokinetic parameters.

11 n between UGT1A1*28 genotype and toxicity or pharmacokinetic parameters.

12 d consistently high oral bioavailability and pharmacokinetic parameters across preclinical animal spe

13 No pharmacokinetic parameters after oral administration wer

14 ere no significant differences in vorinostat pharmacokinetic parameters among the normal or hepatic d

15 ed for only 18% of intersubject variation in pharmacokinetic parameters and 32% to 64% of intersubjec

16 2 hrs after this dose, in order to determine pharmacokinetic parameters and calculate the optimum mai

17 and urine samples were assayed to determine pharmacokinetic parameters and excretion.

18 Blood samples were assayed to determine pharmacokinetic parameters and IGF-1R occupancy on neutr

19 It has more consistent pharmacokinetic parameters and improved bioavailability

20 Population pharmacokinetic parameters and interindividual variabili

21 The compound was shown to have excellent pharmacokinetic parameters and lowered rat plasma LH lev

22 Assessment of associated pharmacokinetic parameters and pharmacokinetic/pharmacod

23 However, the pharmacokinetic parameters and urinary drug clearance in

24 hly valuable resource for the text mining of pharmacokinetics parameters and drug interactions.

25 ot only led to improved metabolic stability, pharmacokinetic parameters, and in vitro activity agains

26 u, including improved in vitro potency, good pharmacokinetic parameters, and in vivo efficacy higher

27 The maximum tolerated dosage, pharmacokinetic parameters, and pharmacokinetic/pharmaco

28 The estimates of radiation dosimetry, pharmacokinetic parameters, and safety profile in this s

29 ed favorable tissue distribution, controlled pharmacokinetic parameters, and significant triglyceride

30 accharides into baboons were used to measure pharmacokinetic parameters, and to assess the extent of

31 ortional manner; isatuximab and lenalidomide pharmacokinetic parameters appeared independent.

32 The nano-OPH pharmacokinetic parameters are improved compared to the

33 te R-13, for which detailed pharmacology and pharmacokinetic parameters are presented.(1)

34 ir physicochemical properties, and attendant pharmacokinetic parameters, are not drug-like.

35 Primary outcomes were the pharmacokinetic parameters area under the curve (AUC) co

36 There were significant differences in pharmacokinetic parameters at 300 mg bid between patient

37 There were no relevant differences in other pharmacokinetic parameters at month 1 or in area under t

38 re highly variable, but measurement of these pharmacokinetic parameters at the start of maintenance w

39 in microparasite abundance is related to the pharmacokinetic parameter, AUC, recording the area under

40 The targeted pharmacokinetic parameters (AUC0-12h and C12h) were achi

41 The insignificant difference in pharmacokinetic parameters between Egyptians and white G

42 poor as a result of moderate variability in pharmacokinetic parameters between patients.

43 The difference in pharmacokinetic parameters between the species is profou

44 though there are differences in some retinal pharmacokinetics parameters between the pigmented and no

45 of any observed CsA concentration, or other pharmacokinetic parameters calculated following a single

46 his bispecific IgG also demonstrated in vivo pharmacokinetic parameters comparable to those of the pa

47 te significant inter-individual variation in pharmacokinetic parameters, concentrations of polyphenol

48 The enhancement and pharmacokinetic parameters correlated significantly with

49 Pharmacokinetic parameters demonstrated that plasma expo

50 In conclusion, PEG-IFN concentrations and pharmacokinetic parameters do not differ between SVRs an

51 Drug pharmacokinetics parameters, drug interaction parameters

52 The main pharmacokinetic parameters estimated were Cmax, Tmax, t1

53 y significant differences were noted for the pharmacokinetic parameter estimates of ara-G between adu

54 y-mass index (BMI), and height Z scores, and pharmacokinetic parameter estimation of ivacaftor.

55 The oral pharmacokinetic parameters for (E,Z)-norendoxifen were d

56 cretion were determined on days 1, 2, and 5; pharmacokinetic parameters for blood samples were determ

57 Pharmacokinetic parameters for PD156707 in dogs are also

58 Pharmacokinetic parameters for the bolus regimen at the

59 istein, daidzein, and glycitein, and defined pharmacokinetic parameters for their absorption and meta

60 Pharmacokinetic parameters for TMZ were calculated by no

61 Human pharmacokinetic parameters for tozadenant and preladenan

62 Pharmacokinetic parameters for volume of the central com

63 f ceftazidime dosing regimens using the mean pharmacokinetic parameters from this population of patie

64 The pharmacokinetic parameter HEF at dynamic gadoxetate-enha

65 sured on enhancement-versus-time curves, and pharmacokinetic parameters (hepatic extraction fraction

66 ced malignancies, characterize the pertinent pharmacokinetic parameters, identify evidence of viral u

67 ermore, several analogues exhibited improved pharmacokinetic parameters in animal models.

68 Pharmacokinetic parameters in children and adolescents w

69 Pharmacokinetic parameters in dogs were evaluated and an

70 The substantial variability in pharmacokinetic parameters in hemophilia patients A pose

71 blood-brain barrier, and displayed favorable pharmacokinetic parameters in mice, rats, and dogs.

72 re, fully human DKK1-IgG displayed favorable pharmacokinetic parameters in non-human primates.

73 (n = 29 ; 11 GG, 10 GT and 8 TT), efavirenz pharmacokinetic parameters in plasma and breast milk dif

74 , whereas HIV status has little influence on pharmacokinetic parameters in pregnant women.

75 improved hCRH1 receptor binding affinity and pharmacokinetic parameters in the rat.

76 BCG2 levels associated with higher erlotinib pharmacokinetic parameters, including area under the cur

77 other genes and evaluated associations with pharmacokinetic parameters, including elimination consta

78 d shutter-speed approach analyses to extract pharmacokinetic parameters, including rate constant for

79 ncidence of chronic rejection and individual pharmacokinetic parameters, including the mean values of

80 Whole blood pharmacokinetic parameters indicated a half-life of 18.2

81 alities that may be important for tuning the pharmacokinetic parameters is also described.

82 considerable variability for DCE MR imaging pharmacokinetic parameters (K(trans), k(ep), v(e), iAUGC

83 For SkBr3, the estimated pharmacokinetic parameters k1 and k3 were consistent wit

84 f cellular potency, physical properties, and pharmacokinetic parameters led to the identification of

85 the drugs delivered individually, while the pharmacokinetic parameters of 17-AAG were similar in bot

86 eveloped for the predictive profiling of key pharmacokinetic parameters of a molecule (adsorption, di

87 The coprimary endpoints were the pharmacokinetic parameters of area under the curve (AUC)

88 The pharmacokinetic parameters of breast cancer were calcula

89 The pharmacokinetic parameters of cantuzumab mertansine, the

90 Differences in the pharmacokinetic parameters of cholinesterases seem to be

91 etween the most critical physicochemical and pharmacokinetic parameters of CNS drugs as well as their

92 Population pharmacokinetic parameters of each drug and between-chil

93 This relationship also held for pharmacokinetic parameters of exposure and 1,5-anhydrogl

94 This work describes the pharmacokinetic parameters of i.v. administered function

95 tissue distribution, metabolic profile, and pharmacokinetic parameters of i.v.-administered N1,N11-d

96 Compartmental pharmacokinetic parameters of isoniazid, rifampin, and p

97 were performed periodically posttransplant; pharmacokinetic parameters of Mut-IL-15/Fc were assessed

98 The pharmacokinetic parameters of RAD showed dose proportion

99 aimed to evaluate the safety, efficacy, and pharmacokinetic parameters of raltegravir (RAL) in human

100 Mean pharmacokinetic parameters of rhuMAb HER2 were unaltered

101 All phase 1 trials showed that pharmacokinetic parameters of the biosimilar and respect

102 lasma samples were taken to characterize the pharmacokinetic parameters of this formulation of CAI.

103 y-4-cholesten-3-one (C4), and changes in the pharmacokinetic parameters of ursodeoxycholic acid and i

104 is to compare the dosage, concentration and pharmacokinetics parameters of tacrolimus between LDLT a

105 in mice revealed substantial improvements in pharmacokinetic parameters over previously reported 1-ad

106 cluding those that are drug related, such as pharmacokinetic parameters, patient-related differences

107 Secondary outcomes were pharmacokinetic parameters, pharmacodynamic effects, ove

108 opyridones, exemplified by 13, with improved pharmacokinetic parameters relative to the initial lead.

109 posomes injected intravenously into rats has pharmacokinetic parameters similar to control, non-pH-se

110 pha-d-mannoside 9, affinity and the relevant pharmacokinetic parameters (solubility, permeability, re

111 Several of these molecules also exhibited pharmacokinetic parameters suitable for in vivo animal s

112 o obtaining excellent kinase selectivity and pharmacokinetic parameters suitable for oral dosing, whi

113 Serial blood samples to calculate pharmacokinetic parameters taken on Day 1 (first ointmen

114 abolite correction and calculation of tissue pharmacokinetic parameters to be achieved.

115 Four primary pharmacokinetic parameters (total clearance, volume of t

116 n describe doxorubicin pharmacokinetics, and pharmacokinetic parameters vary significantly among the

117 Five observers measured pharmacokinetic parameters (volume transfer constant [K(

118 Pharmacokinetic parameters (volume transfer constant, K(

119 No rifamycin pharmacokinetic parameter was consistently and significa

120 een UGT1A1 genotype (n = 61) and toxicity or pharmacokinetic parameters was observed.

121 Mean apolipoprotein A-I pharmacokinetic parameters were as follows: half-life 24

122 Pharmacokinetic parameters were assessed for single and

123 Safety, tolerability, and pharmacokinetic parameters were assessed to evaluate the

124 Pharmacokinetic parameters were calculated after measure

125 Pharmacokinetic parameters were calculated before and af

126 Pharmacokinetic parameters were calculated by noncompart

127 Pharmacokinetic parameters were calculated by noncompart

128 Pharmacokinetic parameters were calculated using a monoe

129 ones were detected by a validated method and pharmacokinetic parameters were calculated using a non-c

130 Tenofovir (TFV) pharmacokinetic parameters were calculated using a nonco

131 Gentamicin pharmacokinetic parameters were calculated using a one-c

132 Pharmacokinetic parameters were calculated.

133 ples for pharmacokinetics were collected and pharmacokinetic parameters were calculated.

134 protein inhibitors, were determined, and the pharmacokinetic parameters were calculated.

135 CPT-11 pharmacokinetic parameters were comparable to those repo

136 Dasatinib pediatric pharmacokinetic parameters were comparable with those in

137 datasets were reconstructed, and parametric pharmacokinetic parameters were compared between the 2 r

138 The estimated pharmacokinetic parameters were compared with expression

139 Whole-tumor-averaged parametric pharmacokinetic parameters were compared with those obta

140 administration during a 24-hr period and the pharmacokinetic parameters were compared.

141 All of the HPPH pharmacokinetic parameters were consistent with a highly

142 Pharmacokinetic parameters were derived from serial whol

143 ect's daptomycin concentration-time data and pharmacokinetic parameters were determined by standard m

144 Pharmacokinetic parameters were determined in a noncompa

145 s investigated in vitro and in vivo, and the pharmacokinetic parameters were determined.

146 rtery, portal vein, and cardiac output), and pharmacokinetic parameters were directly assessed.

147 Pharmacokinetic parameters were estimated by compartment

148 Pharmacokinetic parameters were estimated by fitting the

149 Pharmacokinetic parameters were estimated using a noncom

150 luorotron Master, an ocular fluorophotometer Pharmacokinetic parameters were estimated using WinNonli

151 Plasma pharmacokinetic parameters were evaluated in both normal

152 of absolute neutrophil count (ANC) nadir and pharmacokinetic parameters were evaluated.

153 Pharmacokinetic parameters were evaluated.ResultsForty p

154 uration of dialysis, type of filter, and the pharmacokinetic parameters were extracted from each arti

155 In an in vivo study in mice, lycopene pharmacokinetic parameters were improved by lycopene/OEG

156 Pharmacokinetic parameters were independent of dose and

157 Pharmacokinetic parameters were not prognostic of tumor

158 Pharmacokinetic parameters were obtained by noncompartme

159 VMP were determined by the trapezoid method; pharmacokinetic parameters were obtained using noncompar

160 Pharmacokinetic parameters were similar in children and

161 Although PEG-IFN concentrations and pharmacokinetic parameters were similar in sustained vir

162 Pharmacokinetic parameters were stable over time.

163 ance of CPT enabling simulation of desirable pharmacokinetic parameters with a convenient single-dosi

164 acute lymphoblastic leukemia and correlated pharmacokinetic parameters with disease outcome.

165 oratory values, clinical parameters, and CsA pharmacokinetic parameters with the occurrence of chroni

166 an were obtained during cycle 1 to correlate pharmacokinetic parameters with toxicity.